Understanding virus-host dynamics following EIAV infection in SCID horses

Journal of Theoretical Biology

Volumn 343, Issue , 2014, Pages 1-8

  Ciupe, Stanca M ^a   Schwartz, Elissa J ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Antibody; EIAV; Mathematical models; SCID

Indexed keywords

ANTIBODY; HORSE; HOST-PATHOGEN INTERACTION; MATHEMATICAL ANALYSIS; NEUTRALIZATION; NUMERICAL MODEL; VIRAL DISEASE; VIRUS;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA VIRUS; LENTIVIRUS INFECTION; MACROPHAGE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

ANTIBODY; EIAV; MATHEMATICAL MODELS; SCID;

ANIMALS; COMPUTER SIMULATION; EQUINE INFECTIOUS ANEMIA; HORSES; HOST-PATHOGEN INTERACTIONS; INFECTIOUS ANEMIA VIRUS, EQUINE; MODELS, BIOLOGICAL; MUTATION; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; RNA, VIRAL; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84888779399     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.11.003     Document Type: Article

References (26)

1. Ball C.L., Gilchrist M.A., Coombs D. Modeling within-host evolution of HIV. mutation, competition and strain replacement. Bull. Math. Biol. 2007, 69(7):2361-2385.
2. Bonhoeffer S., May R.M., Shaw G.M., Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 1997, 94:6971-6976.
3. Bryan W.R. Interpretation of host response in quantitative studies on animal viruses. Ann. NY Acad. Sci. 1957, 69:698-728.
4. Ciupe S.M., DeLeenheer P., Kepler T.B. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. J. Theor. Biol. 2011, 277:2011.
5. Cook R.F., Leroux C., Cook S.J., Berger S.L., Lichtenstein D.L., Ghabrial N.N. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J. Virol. 1998, 72:1383-1393.
6. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 1997, 71(5):3840-3852.
7. Hammond S.A., Li F., McKeon B.M., Cook S.J., Issel C.J., Montelaro R.C. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J. Virol. 2000, 74:5968-5981.
8. Hasegawa A., Liu H., Ling B., Borda J.T., Alvarez X., Sugimoto C., Vinet-Oliphant H., Kim W.K., Williams K.C., Ribeiro R.M., Lackner A.A., Veazey R.S., Kuroda M.J. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 2009, 114:2917-2925.
9. Huber M., Trkola A. Humoral immunity to HIV-1. neutralization and beyond. J. Int. Med. 2007, 262:5-25.
10. Leroux C., Cadore J.-L., Montelaro R.C. Equine infectious anemia virus (EIAV). what has HIV's country cousin got to tell us?. Vet. Res. 2004, 35:485-512.
11. Leroux C., Craigo J.K., Issel C.J., Montelaro R.C. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J. Virol. 2001, 75(10):4570-4583.
12. Li F., Leroux C., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J. Virol. 2000, 74:573-579.
13. Maury W., Oaks J.L. Equine Infectious Anemia Virus Pathogenesis and Replication, Lentiviruses and Macrophages. Molecular and Cellular Interactions 2010, Caister Academic Press, Norfolk, UK.
14. Mealey R.H., Fraser D.G., Oaks J.L., Cantor G.H., McGuire T.C. Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency. lessons for control of lentiviruses. Clin. Immunol. 2001, 101(2):237-247.
15. Mealey R.H., Littke M.H., Leib R.S., Davis W.C., McGuire T.C. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals. lack of correlation between in vitro activity and in vivo efficacy. Vet. Immunol. Immunopathol. 2008, 121:8-22.
16. Mealey R.H., Sharif A., Ellis S.A., Littke M.H., Leib S.R., McGuire T.C. Early detection of dominant ENV-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 2005, 339:110-126.
17. Mealey R.H., Zhang B., Leib S.R., Littke M.H., McGuire T.C. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 2003, 313:537-552.
18. Perryman L.E., O'Rourke K.I., McGuire T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 1988, 62:3073-3076.
19. Schwartz, E.J., Vaidya, N.K., Dorman, K., Carpenter, S., Mealey, R.H. Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses, submitted for publication.
20. Taylor S.D., Leib S.R., Carpenter S., Mealey R.H. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses. J. Virol. 2010, 84:6536-6548.
21. Taylor S.D., Leib S.R., Wu W., Nelson R., Carpenter S., Mealey R.H. Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency. J. Virol. 2011, 85:6814-6818.
22. Tomaras G.D., Yates N.L., Liu P., Qin L., Fouda G.G., Chavez L.L., Decamp A.C., Parks R.J. Initial B-cell responses to transmitted human immunodeficiency virus type 1. virion-binding immunoglobulin IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82:12449-124463.
23. Valli V.E. Veterinary Comparative Hematopathology 2007, Ames, Iowa. 1st ed.
24. Weinberger A.D., Perelson A.S. Persistence and emergence of X4 virus in HIV infection. Math. Biosci. Eng. 2011, 8(2):605-626.
25. Wodarz D. Immunity and protection by live attenuated HIV/SIV vaccines. Virology 2008, 378(2):299-305.
26. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W.L., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Natl. Biotechnol. 2010, 28:157-159.